- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01865565
Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
August 7, 2018 updated by: Chun-Nan Yeh, Chang Gung Memorial Hospital
A Trial for Surgical Treatment in Patients With Initially Locally Unresectable Advanced GIST Without Metastasis During Therapy With Imatinib
Gastrointestinal stromal tumors (GISTs) are a form of sarcoma and the most common sarcoma tumors of the gastrointestinal tract.
The limited clinical experience suggests that GIST patients may benefit from neo-adjuvant therapy from primary GIST.
This is a prospective, multicenter, open, observational study in evaluation of safety and efficacy of imatinib compared with that of historical data for locally unresectable advanced GIST without metastasis.
The study will include an up to 28-day screening period, followed by receiving imatinib mesylate (400 mg/day) for at least 6-12 months and followed up for 3 years after surgery.
Study Overview
Status
Completed
Conditions
Detailed Description
Primary Objective
- To observe the safety of imatinib compared with that of historical data for locally unresectable advanced GIST without metastasis.
Secondary Objective
- Progression-free survival (PFS) in resected patients during follow up
- R0 resection rate
- objective response rate, tumor shrinkage rate
- Correlation of mutation status with response
- Correlation of PK with response
- Surgical morbidity and mortality and safety follow up
- Quality of life
- Overall survival (OS)
Study Type
Observational
Enrollment (Actual)
51
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Chang Gung Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study will be conducted in four branch hospitals of Chang Gung Memorial Hospital, Taiwan including Keelung, Linkou, Cha-Yi, and Kaoshung, respectively.
To target 50 patients; 90% patients with response after imatinib treatment; 10% patients without response; compare the result with historical data.
Description
Inclusion Criteria
Locally advanced unresectable GIST without metastasis at
- EC junction requiring total gastrectomy,
- Duodenum requiring Whipple operation;
- Large GIST requiring multiviceral resection;
- Rectum: requiring APR.
- Histologically documentation with positive immunostaining for KIT (CD117)
- Patient age ≥ 18 years old
- ECOG performance status 0 or 1
Patient must have the following post-operative laboratory values confirmed within 14 days prior to registration:
- Creatinine ≤ 1.5 times the institution ULN (upper limit of normal)
- WBC ≥ 3,000/mm3
- Platelets ≥ 100,000/mm3
- Total Bilirubin ≤ 1.5 times the institution ULN. NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study.
- AST ≤ 2.5 times the institution ULN
- ALT ≤ 2.5 times the institution ULN
- Female of childbearing potential must have negative serum pregnancy test. -- -NOTE: Post-menopausal women must be amenorrheic for at least 12 months to be deemed not of reproductive potential.
- Patient is willing to sign informed consent.
Exclusion Criteria
- Patient has received post-operative chemotherapy.
- Patient has received post-operative radiation therapy.
- Patient has received post-operative investigational treatment.
- Patient has received prior therapy with imatinib, or any other molecular targeted or biological therapy.
- Patient has had an active infection requiring antibiotics within 14 days prior to registration.
- any prior malignancies for at least 5 years with potential evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone).
- Patient is deemed by their treating physician to be at risk for recurrence from prior malignancies.New York Heart Association Class 3 or 4 cardiac diseases.
- Patient is taking full dose warfarin. NOTE: The use of mini-dose warfarin (1 mg orally per day) for prevention of central line-associated deep venous thrombosis is permitted.
- Presence of severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal disease, uncontrolled liver disease, including chronic viral hepatitis judged at risk of reactivation, uncontrolled active infection, such as HIV infection, etc.).
- Patient, if female and breastfeeding. NOTE: It is not known whether imatinib or its metabolites are excreted in human milk.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Imatinib treat
• Locally advanced unresectable GIST without metastasis at
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression free survival
Time Frame: five years
|
Evidence of measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines with CT scan.
|
five years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0 resection rate
Time Frame: three years
|
all the participants
|
three years
|
Objective response rate, tumor shrinkage rate
Time Frame: three years
|
all the participants
|
three years
|
Correlation of PK with response
Time Frame: three years
|
check PK (trough level of imatinib)of all the participants at first month and every three months later to correlate with the response and check PK (peak level of imatinib) of all the participants who had adverse events
|
three years
|
Surgical morbidity and mortality and safety follow up
Time Frame: five years
|
surgical morbidity: morbidity related to surgical procedure surgical mortality: mortality related to surgical procedure safety: adverse events related imatinib according to NIH toxicity evaluation criteria
|
five years
|
Overall survival (OS)
Time Frame: five years
|
Overall survival (OS) will be measured from after administration of imatinib mesylate and death as the end point of the study, whatever the cause.
Alive patients will be censored at the date of last follow-up.
Causes of death will be recorded.
|
five years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Chun-Nan Yeh, MD, Chang Gung Memorial Hospital, Linkou, Taiwan.
- Principal Investigator: Jen-Shi Chen, MD., Chang Gung Memorial Hospital, Linkou, Taiwan.
- Principal Investigator: Yen-Yang Chen, MD., Chang Gung Memorial Hospital, Kaoshung, Taiwan.
- Principal Investigator: Kun-Chun Chiang, MD., Chang Gung Memorial Hospital, Keelung, Taiwan.
- Principal Investigator: Liang-Mou Kuo, MD., Chang Gung Memorial Hospital, Cha-Yi, Taiwan.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461.
- Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.
- Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg. 2006 Jun;141(6):537-43; discussion 543-4. doi: 10.1001/archsurg.141.6.537.
- Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002 Oct;8(10):3034-8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2013
Primary Completion (Actual)
December 31, 2016
Study Completion (Actual)
December 31, 2017
Study Registration Dates
First Submitted
May 22, 2013
First Submitted That Met QC Criteria
May 28, 2013
First Posted (Estimate)
May 31, 2013
Study Record Updates
Last Update Posted (Actual)
August 9, 2018
Last Update Submitted That Met QC Criteria
August 7, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Yeh CN001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Stromal Tumor
-
Hospital Universitario Virgen de la ArrixacaNot yet recruitingLiver Diseases | Liver Transplantation | Liver Neoplasms | Gastrointestinal Stromal Tumors | Metastasis | Liver Metastases | Liver Transplant; Complications | Liver Cancer | Liver Transplant Disorder | Liver Carcinoma | GIST, Malignant | GIST | Metastases | Metastatic Liver Cancer | Gastrointestinal Stromal Tumor of... and other conditionsSpain
-
Centre Leon BerardRecruitingMetastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)France
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Gastrointestinal Stromal Tumor | Metastatic Sarcoma | Locally Advanced Sarcoma | Locally Advanced Gastrointestinal Stromal Tumor | Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal... and other conditionsUnited States
-
Centre Leon BerardRecruitingC-KIT Mutation | Metastatic Gastrointestinal Stromal Tumor (GIST) | Advanced Gastrointestinal Stromal Tumor (GIST)France
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.RecruitingSolid Tumor, Adult | Gastrointestinal Stromal Tumor (GIST)China
-
ARCAGY/ GINECO GROUPRoche Pharma AGCompleted
-
Assaf-Harofeh Medical CenterUnknownSoft Tissue Sarcoma | Osteosarcoma | Chondrosarcoma | Bone Sarcoma | Desmoplastic Small Round Cell Tumor | Gastrointestinal Stromal Sarcoma | Ewing's Tumor Metastatic | Ewing's Tumor Recurrent
-
AB ScienceCompletedGastro Intestinal Stromal TumorFrance
-
Institut BergoniéFrench Sarcoma GroupRecruitingGastro Intestinal Stromal TumorFrance
-
University Medical Center GroningenDutch Cancer SocietyRecruitingGastro-intestinal Stromal TumorNetherlands